Prof. Andras Lacko

Dr. Lacko acquired knowledge, research expertise, and determination to execute research studies during his career successfully. He was initially trained in protein chemistry and enzymology and subsequently developed a particular focus on studying lipoprotein structure/function and metabolism at the University of Washington in Seattle. His most recent research involved evaluating a lipoprotein-based, biocompatible drug delivery system primarily directed toward improving cancer chemotherapy. As a PI or co-investigator on several grants funded by NIH and other organizations, including CDMRP, AHA, CPRIT, and private funding organizations), he led the work that allowed the establishment of solid proof of concept for the research reported in this communication. These findings included enhancement of the therapeutic efficacy of anti-cancer agents via the use of reconstituted high-density lipoprotein (rHDL) nanoparticles (NPs) as delivery vehicles. Specifically, his work supported the concept that by using rHDL nanoparticles as a drug transport system, selective delivery of anti-cancer agents, via a receptor (SR-B1) mediated mechanism, to tumors could be achieved. Throughout his career, Dr. Lacko sought the collaborative participation of clinical investigators to facilitate the advance our research findings at the bedside. This led to collaborative work, and two approved patents with Dr. Sood, fat MD Anderson Cancer Center and Dr. Alan Remaley at the NIH.